URGNUroGen Pharma Ltd.vs its industry peers
A metric-by-metric comparison of UroGen Pharma Ltd. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| URGNEsta | $1.6B#2 | — | — | 14.6x#4 | 21.4%#3 | -21.0%#3 | -113.7%#4 | — | — | 2#1 | 64.9%#2 | — |
| TLPPF | — | — | — | — | 55.6%#1 | -121.2%#4 | 3.7%#1 | — | — | — | — | — |
| TLX | $3.1B#1 | — | — | 3.8x#2 | 55.6%#1 | -121.2%#4 | 3.7%#1 | — | — | — | -14.9%#3 | — |
| UPC | $875991#4 | — | 0.0x#1 | 0.0x#1 | -22.4%#5 | 57.9%#1 | -16.3%#3 | -6.5%#1 | -4.6%#1 | — | 519.1%#1 | 1827.1%#1 |
| VCNX | $4M#3 | — | 0.5x#2 | 6.1x#3 | 5.4%#4 | 8.0%#2 | -3117.3%#5 | -251.4%#2 | -296.0%#2 | — | -63.3%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-02.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice